Statement of Unaudited Financial Result for the quarter ended on 30th September, 2025 alongwith Limited Review Report.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Denis Chem Lab reported Q2 FY26 revenue from operations of Rs. 4,617.13 lakh, down about 3.4% from Rs. 4,781.76 lakh in the year-ago quarter. Profit after tax for the quarter fell sharply to Rs. 221.25 lakh vs. Rs. 353.06 lakh in Q2 FY25, a decline of roughly 37%. For the half year ended September 2025, revenue was nearly flat at Rs. 8,944.72 lakh versus Rs. 8,907.50 lakh a year ago, while H1 PAT dropped about 16% to Rs. 468.75 lakh. EBITDA margins compressed due to higher employee, depreciation, and finance costs, and operating cash flow for the half year turned negative at Rs. (83.94) lakh compared with a strong positive year-ago period. Short-term borrowings jumped sharply to Rs. 753.09 lakh from Rs. 36.73 lakh, and trade receivables ballooned to Rs. 4,209.92 lakh from Rs. 3,061.48 lakh. The auditors (Shah & Shah Associates) issued an unmodified review report, and a 15% dividend (Rs. 1.50 per share) was approved at the AGM.
Higher working-capital strain, rising short-term debt, weaker margins, and a PAT decline year-on-year may pressure the stock in the near term, though the clean audit opinion and ongoing dividend provide some support.